A pooled analysis of 2310 patients with HER-2− breast cancer from four prospective clinical trials using neoadjuvant therapies showed that compared with HER-2− type, HER-2-low had a relatively lower histological grade (grade III) and lower Ki-67 score. Here, MKI67 is linked to breast carcinoma.